

Date: 05th November, 2024

To

The Listing Department

National Stock Exchange of India Limited

Exchange Plaza,

Bandra - Kurla Complex

Bandra (East)

Mumbai - 400 051

Stock Code: INDOCO-EQ

То

The Listing Department

Bombay Stock Exchange Limited

Floor 25, P. J. Towers,

Dalal Street,

Mumbai - 400 001

Stock Code: 532612

Dear Sir/Madam,

Subject: Appointment of Senior Management Personnel

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that on basis of recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company on 05th November, 2024 through resolution by circulation have approved the appointment of Mr. Vaibhav Sinha as Senior Management Personnel designated as Vice President- Business Development-Rest of the World of the Company with effect from 05th November, 2024.

The details as required to be disclosed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 has been provided in Annexure A to this letter.

Thanking you, Yours faithfully, For Indoco Remedies Limited

Ramanathan Hariharan Company Secretary & Head- Legal



Annexure A

Name	Mr. Vaibhav Sinha
Reason for change viz. appointment, re-	Appointment of Mr. Vaibhav Sinha as
appointment, resignation, removal, death	Senior Management Personnel designated
or otherwise	as Vice President- Business Development-
	Rest of the World of the Company with
	effect from 05th November, 2024
Date of appointment / re-appointment	Date of Appointment: 05th November, 2024
/cessation (as applicable) & term of	Terms of Appointment: Full time
appointment/re-appointment	employment
Brief profile (in case of appointment);	Mr. Vaibhav Sinha is a commerce graduate
	and has completed MBA in International
	Business from Delhi School of Economics
	and PG Diploma in Finance from Institute of
	Management Sciences.
	He has 19+ years industry experience with
	global companies like Sun Pharma, Ranbaxy
	and DSM with exposure to multiple product
	segments and markets.
	He was last employed with Sun Pharma as
	Head of Business Development, Licensing,
	Portfolio and Acquisitions (Asia and Africa).
	He has expertise in licensing (In/Out),
	M&A, portfolio planning, new launches,
	business strategy and analysis, techno-
	commercial due diligence, deal structuring
	with hands on exposure of working for
	NCEs, Biologics/Biosimilars, Rx, OTC and
Did to the transfer	complex products.
Disclosure of relationships between	Not Applicable
directors (in case of appointment of a	
director).	

